This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Growth Stocks to Tap the COVID-Driven Shift in MedTech
by Urmimala Biswas
To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.
Is Quest Diagnostics (DGX) a Worthy Pick for Value Investors?
by Zacks Equity Research
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Quest Diagnostics (DGX) Grows on Two New Lab-Service Pacts
by Zacks Equity Research
Quest Diagnostics (DGX) is moving ahead in terms of its growth strategy, which consists of five elements.
Quest Diagnostics (DGX) Down 1.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Winnebago Industries, Meritage Homes, Pampa Energia, Quest Diagnostics and The Michaels Companies
by Zacks Equity Research
Zacks.com featured highlights include: Winnebago Industries, Meritage Homes, Pampa Energia, Quest Diagnostics and The Michaels Companies
5 High Earnings Yield Stocks That Make Attractive Bets
by Rimmi Singhi
If you are not sure whether to invest your money in bonds or stocks, a key parameter that can show you the right direction is earnings yield.
LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service
by Zacks Equity Research
Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.
BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark
by Zacks Equity Research
BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.
OPKO Health's (OPK) BioReference Laboratories Unveils New Test
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.
Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises
by Zacks Equity Research
In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 14.93% and 1.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Quest Diagnostics (DGX) Might Surprise This Earnings Season
by Zacks Equity Research
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Higher Testing to Aid Quest Diagnostics' (DGX) Q3 Earnings
by Zacks Equity Research
Quest Diagnostics (DGX) is expected to report strong improvement in COVID-19 antibody and molecular diagnostic testing volume in Q3.
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $116.67 in the latest trading session, marking no change from the prior day.
Quest Diagnostics (DGX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $116.21 in the latest trading session, marking a +0.71% move from the prior day.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics' 3-in-1 Coronavirus Test Launch Well Timed
by Zacks Equity Research
According to Quest Diagnostics (DGX), under such situation, laboratory testing that can reliably identify the virus causing disease will be critical to mobilize effective patient care.
3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown
by Sriparna Ghosal
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.
Quest Diagnostics (DGX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $114.49 in the latest trading session, marking a +0.74% move from the prior day.
Quest Diagnostics Partners in Pilot Program for COVID-19 Test
by Zacks Equity Research
Quest Diagnostics (DGX) to provide online test results for COVID-19 samples collected via drone-delivered at-home self-collection kits as part of a pilot program.
Quest Diagnostics (DGX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $109.19 in the latest trading session, marking a -1.91% move from the prior day.
DGX, NKLA, NKE and TSLA as Zacks Bull and Bear of the Day
by Zacks Equity Research
DGX, NKLA, NKE and TSLA as Zacks Bull and Bear of the Day
Why You Shouldn't Bet Against Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Quest Diagnostics (DGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Bull Of The Day: Quest Diagnostics (DGX)
by Daniel Laboe
Quest Diagnostics (DGX) has been one of the coronavirus heroes, having performed 14.4 million COVID-19 diagnostics tests and 3.6 million antibody tests